Transgenic mice engineered to overexpress the HER-2/ neu/erbB-2 protooncogene under the control of a mammary-speci®c promoter develop mammary tumors and are a model for human breast cancer. Signal transduction by Neu was examined in situ in the tumors of these transgenic mice. This was accomplished using the PN2A monoclonal antibody, which recognizes Neu only in the phosphorylated, and therefore actively signaling, state. Immunohistochemistry using PN2A demonstrated that Neu actively signals in the tumors of Neu transgenic mice. Expression of Neu was always accompanied by co-overexpression of the endogenous epidermal growth factor receptor. Qualitatively similar results were found in mammary tumors from mice bitransgenic for the neu and transforming growth factor-a genes (both driven by the mouse mammary tumor virus promoter). Early mammary lesions demonstrated distinctive patterns of Neu activation relative to expression levels. Overexpression and activation were separable both temporally and spatially. These results re®ne the multi-step model for the role of Neu in mammary neoplasia and establish phosphorylation-state speci®c antibodies as a powerful tool for investigating tumor progression.
Neu is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (Bargmann et al., 1986b; Coussens et al., 1985; Stern et al., 1986; Yamamoto et al., 1986) . Although a directly activating ligand for Neu has not been identi®ed to date, this receptor can be activated by several mechanisms, including high level overexpression (Di Fiore et al., 1987; Hudziak et al., 1987; Pierce et al., 1991; Stern et al., 1988) , mutational activation (Bargmann et al., 1986a; Bargmann and Weinberg, 1988; Siegel et al., 1994; Stern et al., 1988; Weiner et al., 1989) and transmodulation (Carraway et al., 1994; Goldman et al., 1990; Plowman et al., 1993; Riese et al., 1995 Riese et al., , 1996 Stern et al., 1986; Stern and Kamps, 1988; Tzahar et al., 1996; Wada et al., 1990 ) (and reviewed in Riese and Stern, in press) , in which ligand binding to other receptors in this family results in receptor heterodimerization between two members which are co-expressed. Such heterodimerization results in transphosphorylation and activation of both receptors in the complex.
The neu gene is ampli®ed and the protein overexpressed in a large subset of human breast carcinomas and this event has been implicated in both tumorigenesis as well as tumor progression (reviewed in Hynes and Stern, 1994) . Overexpression has been reported to be an adverse prognostic indicator (Slamon et al., 1987 (Slamon et al., , 1989 . To study the role of Neu in mammary tumorigenesis and progression in vivo, several strains of mice transgenic for the neu gene under the control of the mouse mammary tumor virus (MMTV) promoter/ enhancer have been engineered resulting in their spontaneous development of mammary carcinomas (Bouchard et al., 1989; Guy et al., 1992b Guy et al., , 1996 Lucchini et al., 1992; Muller et al., 1988; Suda et al., 1990) . In addition, female mice transgenic for two of the EGF family ligands, MMTV- (Matsui et al., 1990) or metallothionein- (Sandgren et al., 1990 ) directed transforming growth factor-a (TGFa) and MMTVNeuregulin (NRG) b2c (Krand and Leder, 1996) , also develop focal mammary adenocarcinomas, further implicating an etiologic role for excessive signaling through EGFR family receptors in mammary transformation.
The MMTV-wild type rat neu transgenic mice used in this study develop unifocal mammary tumors after long latency (Guy et al., 1992b) . The long latency period suggests the requirement for additional events in a multi-step process of tumorigenesis. One step is overexpression, since, in these mice, tumors have been found to contain 10 ± 50-fold elevated levels of transgene mRNA compared to adjacent non-tumor mammary tissue and in tumor extracts Neu protein is detectable at levels higher than that detected in extracts of adjacent normal epithelium (Guy et al., 1992b) . Another event induces activation, since, unlike Neu from adjacent normal epithelium, Neu from tumor extracts undergoes autophosphorylation when examined by in vitro kinase assays (Guy et al., 1992b) . In addition, in many of the tumors from these mice, activating somatic mutations had been acquired in the transgene which contributed to tumor progression (Siegel et al., 1994; Siegel and Muller, 1996) .
The previous genetic and biochemical studies provide important information on the role of Neu in mammary carcinogenesis. However, these approaches have a number of limitations. The requirement for soluble tissue extracts to perform in vitro kinase assays introduces variables that may not re¯ect the natural state in situ. Additionally, information available from examining tissue architecture is lost in such experiments. Dierential regulation of Neu in areas of hyperplasia or dysplasia, as well as heterogeneity within tumors, may provide critical clues regarding the role of Neu in neoplastic progression.
Although immunohistochemistry is the most commonly employed method to study expression of proteins in situ in tissue specimens, with preservation of tissue histology and the spatial information regarding the distribution of expression, the principle limitation of this technique is that no information is revealed about the biochemical activity of a protein or the signaling pathways activated in the tissue. In order to preserve the histological detail while at the same time assaying for biochemical activity in situ, we have produced a monoclonal antibody, PN2A, which detects Neu only in its phosphorylated, and therefore activated, state (DiGiovanna et al., 1996; DiGiovanna and Stern, 1995) . This reagent, therefore, can be used in immunohistochemical staining of tumor sections to probe tumors in situ not only for levels of expression of Neu, but also for the degree of signaling by Neu.
Use of PN2A staining as a marker of signaling activity relies on the assumption that phosphorylation at this epitope (Tyr1248) can be equated with actively signaling receptor. This is a sound assumption based upon the known biology of Neu and the eects of altering this site in particular. Tyr1248 is the autophosphorylation site which appears to be most tightly linked to oncogenic transformation (Akiyama et al., 1991; Mikami et al., 1992 ; but see Segatto et al., 1990) and coupling to the ras/MAP kinase signaling pathway (Ben-Levy et al., 1994) . The latter pathway appears to be important in transducing the mitogenic signals from this family of receptors. We acknowledge, however, that individual autophosphorylation sites may be regulated independently and we have reported isolation of Neu which is dephosphorylated at this site but phosphorylated at other sites (DiGiovanna, 1997) . The functional output of such a receptor is currently unknown, but it is possible that particular signals, potentially non-mitogenic in nature, may be transmitted.
Neu expression in MMTV-Neu transgenic mice
Mammary tumors from six MMTV-wild type rat neu transgenic mice (Guy et al., 1992b) were stained immunohistochemically for Neu expression, and all were found to be positive. A representative section is shown in Figure 1b (see also Table 1 ). Distinct membrane staining was used as the criterion for positive staining (DiGiovanna et al., 1996; DiGiovanna and Stern, 1995) . This staining was blocked by preincubation of the primary antibody with synthetic peptide corresponding to the antigenic epitope, demonstrating the speci®city of the staining reaction. Staining was rarely visible in normal mammary epithelium adjacent to tumors and when observed, it was generally basolateral in distribution. The ®nding of occasional staining for Neu in adjacent normal mammary epithelium of the transgenic mice suggests that the cells with such staining may be those destined to progress to hyperplasia and/or neoplasia. Normal, uninvolved mammary glands from Neu transgenic mice did not stain for Neu, consistent with the ®nding that tumors express 10 ± 50-fold higher levels of transgene mRNA than adjacent normal mammary tissue (Guy et al., 1992b) . These staining results are consistent with the conclusion that the immunohistochemical assay only detects overexpressed levels of the product of the transgene in the tumors, whereas lower levels found in normal tissue are largely undetectable. These results parallel the experience in human breast tumors, in which normal, low levels of this receptor are undetectable by immunohistochemistry in paran sections, but positive staining correlates with overexpression as determined by other means (Press et al., 1990; Slamon et al., 1989) . Immunoreactive Neu was not detectable in mammary tissue from wild type mice, or in the mammary tumors induced in MMTVpolyomavirus middle T (mT) transgenic mice (Guy et al., 1992a ) (data not shown). Hence, these results provide an in situ demonstration that Neu protein expression is elevated in tumors from Neu transgenic mice compared to normal adjacent mammary tissue from these mice and that Neu overexpression does not occur in mammary tissue from normal mice or mammary tumors arising by a dierent molecular mechanism. These results corroborate earlier studies in which transgene expression was measured by mRNA analysis or by immunoblotting of tissue extracts (Guy et al., 1992b) .
Neu phosphorylation in MMTV-Neu transgenic mice
When these same tissues were stained with the PN2A antibody which speci®cally detects the phosphorylated, and therefore activated, species of Neu, the receptor was found to be phosphorylated in all tumors from the MMTV-Neu transgenic mice (Figure 1a and c) . Adjacent normal mammary epithelium rarely demonstrated membrane staining. Tumor staining was (d) is most intense at the periphery of the tumor, while the phospho-Neu stain in these panels is the most intense on the membrane of larger mid-zone cells (a and c). This pattern was seen in serial sections from the same tissue block. Sections were counterstained with hematoxylin (5006). Images were captured using a Kontronics camera model 8012, on an Olympus BH2 microscope and digitized using Photoshop 4.0 with the Kontronics`plug-in' module, color enhanced, converted from RGB to grayscale, balanced for contrast and brightness and printed on a Kodak 8650 dye sublimation printer. Mice were sacri®ced by CO 2 inhalation followed by cervical dislocation. Tumors or normal tissues were excised, immediately ®xed in zinc-formalin solution and processed for paran embedding by routine procedures. Detection was by the peroxidase anti-peroxidase procedure (DiGiovanna et al., 1996) or an avidin:biotinylated enzyme complex procedure (Vector Laboratories Inc., Burlingame, CA). Antibodies were as follows: for Neu, Ab3 (Oncogene Science, Inc., Manhasset NY), CB11 (Novocastra Laboratories Ltd., Newcastle upon Tyne, UK) and a rabbit polyclonal produced by WJM; for phosphorylated Neu, PN2A (DiGiovanna and Stern, 1995); and anti-EGFR (Gibco ± BRL, Gaithersburg MD)
blocked by pre-incubation of the primary antibody with synthetic phosphorylated peptide corresponding to the antigenic epitope, but not by incubation with the corresponding non-phosphorylated peptide, indicating speci®city of the staining for phosphorylated Neu. Normal mammary tissue from MMTV-Neu transgenic mice, as well as mammary tissue from wild type mice or mammary tumors from MMTV-mT transgenic mice, did not stain for phosphorylated Neu, which was expected since the receptor itself was undetectable in these tissues. Hence, these results demonstrate in situ that Neu is overexpressed and is actively signaling in the tumors from Neu transgenic mice.
EGFR expression in MMTV-Neu transgenic mice
Since the EGFR can transactivate Neu, it was of interest to examine these specimens for expression of EGFR. EGFR was undetectable in mammary tissue from wild type mice, again indicating that the normal low levels of expression are not detectable by immunohistochemistry in paran sections. On the contrary, endogenous EGFR was readily detectable in the tumors from MMTV-Neu transgenic mice ( Figure  1d ) and was rarely visible in adjacent normal mammary epithelium. Moreover, endogenous EGFR was detectable in mammary tumors from MMTV-mT transgenic mice, but speci®cally in areas of the tumors demonstrating squamous dierentiation (data not shown). Although EGFR has been associated with mammary gland malignancy in both human and animal systems, regulation of EGFR expression by Neu signaling has not been reported. It has been shown in cultured cells that EGF can elicit increases in EGFR mRNA and protein levels over a time course of several hours (Clark et al., 1985) . Our data suggest that activation of Neu may also result in upregulation of EGFR levels. The ®nding of EGFR overexpression in the mammary tumors of MMTV-mT mice, though, suggests that the EGFR may be a common component of murine mammary carcinogenesis. However, in MMTV-mT mice, EGFR was detected in areas of squamous histology, suggesting a possible role in a divergent pathway of terminal dierentiation to squamous cells rather than in tumorigenesis. Upregulation of EGFR in mT tumors likely ampli®es an autocrine stimulatory loop, since mT transformed cells produce TGFs (Kaplan and Ozanne, 1982) .
MMTV-TGFa transgenic and MMTV-TGFa x MMTV-Neu bigenic mice
Mice transgenic for MMTV-TGFa (Matsui et al., 1990) , a ligand for the EGFR and bitransgenic for MMTV-TGFa and MMTV-Neu , were examined to evaluate a potential interaction between these two receptor systems. The bitransgenic mice develop multifocal mammary tumors which may encompass the entire gland and develop these tumors with a latency much shorter than animals bearing either transgene alone. Tumors in these mice are either of the Neu type (nodular) or the TGFa type (tubular), but mixed histology within a given tumor is not seen. It was previously reported that in the tumors of these animals, Neu protein was tyrosine phosphorylated, but activating deletion mutations were not detected. This suggested that Neu was activated instead through transmodulation via the TGFa/EGFR system. Multiple tumors, hyperplasias and/or cysts were examined from two monogenic and two bigenic mice. Neu, phosphorylated Neu and EGFR were all undetectable by immunohistochemistry in either tumors, hyperplasias or cysts from mice monotransgenic for MMTV-TGFa. In tumors from MMTVTGFa x MMTV-Neu bitransgenic mice, staining was positive for Neu overexpression. Staining for EGFR was positive in the tumor, in areas of dysplasia and occasionally in adjacent normal mammary epithelium. This is surprising since the tonic production of TGFa might be expected to elicit ligand-induced down-regulation of EGFR. Of note, however, are ®ndings, discussed above, that EGF can upregulate EGFR mRNA and protein experimentally over a course of several hours in cultured cells (Clark et al., 1985) and that EGFR mRNA levels were upregulated in the MMTV-TGFa mice (Matsui et al., 1990) .
Since TGFa-stimulated activation of EGFR would be capable of transmodulating Neu, it was predicted that these tumors would stain strongly for phosphorylated Neu with the PN2A antibody. However, PN2A staining was absent, or weak and patchy, and not nearly as strong as seen in the Neu monotransgenic mice. The staining pattern for all three antibodies was similar in cysts from the TGFa x Neu bitransgenic mice. Hence the lesions from the bitransgenic mice have elevated levels of both Neu and EGFR, yet despite constitutive production of an EGFR ligand (TGFa), these tumors demonstrate somewhat less Neu signaling activity (phosphorylation) than seen in Neu Figure 2 Schematic model of Neu activity in a mammary tumor of a Neu transgenic mouse. Neu overexpression occurs in all of the shaded areas, while Neu is highly phosphorylated mainly in the black and gray areas. The black phospho-Neu-positive area harbors cells which are larger and have more abundant, clear cytoplasm than cells in the remainder of the tumor, and this area harbors the most mitoses. Hence the black area is hypothesized to be a`growth zone'. Autocrine production of a Neu-activating ligand may occur in this zone monotransgenic mice. The most likely explanation is that activation by mutation, seen in Neu monogenic mice but not in the bigenics, is more ecient than activation by transmodulation. Selective pressure for mutational activation may occur with greater frequency when other mechanisms of activation are not readily available. It has also been reported that TGFa is a less ecient transactivator of Neu than is EGF (Gulliford et al., 1997) .
Spatial distribution of Neu and phosphorylated Neu in mammary tumors
A striking aspect of the immunohistochemical assays for Neu and phosphorylated Neu in the MMTV-Neu transgenic mice was that the staining observed was not uniform throughout a given tumor. Tumors were harvested when approximately 1 cc in size. Staining for Neu was most intense around the periphery of each tumor, typically extending 15 ± 25 cells deep ( Figure  1b) . This staining was speci®c and not due to edge artifact, since it was not observed in the presence of blocking peptide or when staining was performed with an isotype-equivalent irrelevant antibody. The absence of staining in the central areas of the tumors did not appear to be due to ®xation artifact, since identical patterns were found using specimens ®xed by a variety of methods, including perfusion of live, anesthetized animals and using specimens prepared in our dierent laboratories at dierent institutions. We have previously reported this expression pattern for Neu in mammary tumors from MMTV-Neu transgenic mice (Deckard-Janatpour et al., 1997).
The staining pattern for phosphorylated Neu overlapped with but did not precisely mirror that of Neu, even when performed on serial sections of the same tissue block. Phosphorylated Neu was detected most strongly near the periphery of tumors, but unlike Neu, was not strongest closest to the edge (Figure 1a and c) . Figure 3 Immunohistochemical staining for Neu and phosphorylated Neu in pretumorous dysplastic lesions of MMTV-Neu transgenic mice. Digital images of the immunoperoxidase stain using anti-phospho-Neu (PN2A) (a and c) and anti-Neu (Ab3) (b and d) are shown, illustrating their distribution in type 1 (a and b) and type 2 (c and d) dysplastic lesions of the transgenic Neu mammary gland. Note that the type 1 dysplastic mass is phospho-Neu positive and Neu negative (actually Neu weak and patchy under direct microscopy) (a and b). These sections were counterstained with hematoxylin. The type 2 dysplasia is strongly positive for Neu but negative for phospho-Neu (c and d). These sections were counterstained with ethyl green. (2506). Methods were as in Figure 1 In addition, there were two circumferential bands of distinct histologic appearance within the phosphorylated Neu-containing tissue (Figure 1a and c; see also Figure 2 ). The more peripheral cells staining for phosphorylated Neu tended to be relatively large, with abundant clear cytoplasm and the most abundant mitoses observed anywhere in the tumor. The more central cells staining for phosphorylated Neu had smaller nuclei, more compact chromatin, less abundant cytoplasm and no mitoses. The center of the tumor did not stain at all for Neu, and contained nonproliferating, small cells with condensed nuclei and sparse cytoplasm.
Model for tumor growth
The histochemical information obtained from staining for phosphorylated Neu contributes substantially to the interpretation of these staining patterns. The spatial separation of Neu expression and activation suggests a model of tumor growth in which the outermost margin expresses the highest levels of Neu and immediately interior to the outer margin is the area of greatest proliferative activity (a`growth zone'), where autocrine production of a factor that activates Neu likely occurs, resulting in cell division. A schematic representation of this model is presented in Figure 2 . An alternative Figure 4 Comparison of Neu expression and activation in murine versus human mammary carcinogenesis. In the murine model, the pathway on the left represents that of the type 2 intermediate lesions (staining positively for Neu overexpression, but negatively for phosphorylation). The pathway on the right represents that of the type 1 intermediate lesion (low levels of Neu, but strong staining for phosphorylated Neu). In the human model, the progression from hyperplasia to DCIS to invasive carcinoma is hypothetical. Neu is phosphorylated in roughly 1/2 (DiGiovanna et al., manuscript in preparation) and 1/3 (DiGiovanna et al., 1996) of the cases of DCIS and invasive carcinoma, respectively, in which it is overexpressed hypothesis would be that this`growth zone' represents a cell clone in which Neu has been activated by somatic mutation. However, the ligand-activation model is favored because the spherical spatial distribution of phosphorylated Neu appears most consistent with a pattern of diusion of a soluble ligand. The production of such ligand would likely come from within the tumor mass, rather than from the exterior of the tumor, because the Neu at the outermost edges of the mass is least phosphorylated. Growth factor independence may be selected for later by the acquisition of activating somatic mutations.
Pretumorous lesions in MMTV-Neu transgenic mice
On four occasions a microscopic neoplastic lesion was detected in otherwise grossly normal (uninvolved) mammary glands from Neu transgenic mice. Two opposing staining patterns were found in these types of lesions. Three lesions (type 1 pattern) appeared to represent atypical hyperplasias and stained relatively weakly for Neu but strongly for phosphorylated Neu (with occasional staining even in some of the adjacent normal mammary epithelium), indicating a relatively low level of receptor but which is highly active in signaling (Figure 3a and b) . One lesion representing a small tumorlet (type 2 pattern), on the contrary, stained strongly for Neu but did not stain for phosphorylated Neu (Figure 3c and d) . Both types stained positively for EGFR. A summary of all staining patterns is presented in Table 1 .
Model for tumor progression
These pretumorous lesions likely represent intermediate steps in two parallel pathways of tumor progression. As such, type 1 lesions express receptor that is highly active in signaling, but expressed at low levels. A mutationally-activated receptor could account for this pattern. In contrast, type 2 lesions express elevated levels of receptors but which have not yet been activated to signal. These lesions suggest that full tumor development requires at least two events: upregulation of levels of expression and speci®c activation of signaling. The necessity for these two temporally discrete events may account for the latency in MMTV-wild type neu transgenic mice compared to MMTV-oncogenic neu transgenic animals.
Hence, a minimal model based on our evidence would include at least four states existing within one of two alternative pathways (Figure 4 ): (i) low level expression of the transgene in mammary epithelia; (ii) high level expression of the transgene in mammary epithelia; receptor is not yet signaling to a signi®cant extent, and thus an intermediate neoplastic lesion results; or (iii) expression of ligand-or mutationallyactivated receptor, but at low levels, again resulting in an intermediate neoplastic lesion; (iv) high level expression of an activated receptor resulting in full tumor phenotype. Induction of overexpression of cosignaling receptors, in particular the EGFR, is also an early event, occurring at or before the intermediate stages. Some transgenic mice expressing the oncogenically mutated form of constitutively activated Neu appear to require no additional events for tumorigenesis (Guy et al., 1996; Muller et al., 1988) , apparently proceeding via a type 2 pathway but bypassing the second step involving acquisition of receptor activation (but see Bouchard et al., 1989 , in which oncogenically activated Neu results in the stochastic appearance of mammary tumors).
It is instructive to contrast the murine model with observations made in human breast cancer. In human breast disease, overexpression of Neu is not associated with benign lesions (Schimmelpenning et al., 1992) . However, it is not clear that the benign breast lesions or even in situ carcinoma in humans are invariably intermediates in a progression to a malignant state. Overexpression is found most frequently, however, in ductal carcinoma in situ (DCIS) and paradoxically less frequently in invasive carcinoma. In addition, we have found using the PN2A antibody that the receptor is actively signaling (phosphorylated) in only a proportion of both invasive and DCIS lesions (DiGiovanna et al., 1996; DiGiovanna and Stern, 1995) . A diagram depicting this emerging model of the contribution of Neu to tumor progression in mice and humans is shown in Figure 4 . While the diering histologies do not allow an exact alignment of stages, it is clear that this murine system serves as a useful model to understand the role of Neu in mammary carcinogenesis. The utilization of activation state-dependent antibodies permits the dissection of these pathways in ways not previously possible.
